Since human pancreatic cancer has certain
immunological characteristics of the mouse model, a phase 1 clinical trial of AMD3100 in patients with pancreatic cancer will be initiated in 2015.
We expect that the CRI iAtlas will help to accelerate discovery and improve patient outcomes by providing researchers greater access to genomics data to better understand
the immunological characteristics of the tumor microenvironment and its potential impact on patient responses to immunotherapy,» said Jill O'Donnell - Tormey, Ph.D., CEO and director of scientific affairs at CRI.